Marco Proietti1, Valeria Raparelli2, Brian Olshansky3, Gregory Y H Lip4,5. 1. Centre for Cardiovascular Sciences, City Hospital, University of Birmingham, Birmingham, UK. marco.proietti@uniroma1.it. 2. I Clinica Medica, Sapienza-University of Rome, Rome, Italy. 3. Division of Cardiovascular Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. 4. Centre for Cardiovascular Sciences, City Hospital, University of Birmingham, Birmingham, UK. g.y.h.lip@bham.ac.uk. 5. Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. g.y.h.lip@bham.ac.uk.
Abstract
BACKGROUND:Polypharmacy, as the use of five or more drugs, has commonly been associated with the elderly and multiple co-morbidities and related to impairment of clinical state and adverse outcomes, in general population. Limited data are available on the relationship between polypharmacy and adverse outcomes in atrial fibrillation (AF). We describe the prevalence of polypharmacy and AF, and its association with major adverse events, such as stroke and cardiovascular (CV) death. METHODS AND RESULTS: For this study, we analysed all AFFIRM Trial patients with complete pharmacological data. Polypharmacy was recorded in 40 % of 4056 AF patients. The crude incidence of CV death was 3.45 % patient-years among patients with polypharmacy, vs 1.65 % patient-years without polypharmacy. Kaplan-Meier analysis showed that patients with polypharmacy had a higher cumulative incidence of CV death (p < 0.001). Cox regression analysis demonstrated that female gender (p = 0.038), diabetes mellitus (p = 0.029), previous myocardial infarction (MI) (p = 0.004), prior stroke (p = 0.011) and polypharmacy (p = 0.029) were independently associated with CV death. Polypharmacy was associated with an adjusted relative risk of 1.30 (95 % CI 1.03-1.64) for CV death. A linear increase in the number of drugs was significantly associated with CV death. No significant association was found with stroke occurrence. CONCLUSIONS:Polypharmacy is highly prevalent in AF patients and associated with a worse clinical outcome, conferring 30 % excess relative risk for CV death. Thus, polypharmacy may be a health status marker. Strategies to reduce inappropriate prescription and polypharmacy should be tested in prospective longitudinal studies of AF patients.
RCT Entities:
BACKGROUND: Polypharmacy, as the use of five or more drugs, has commonly been associated with the elderly and multiple co-morbidities and related to impairment of clinical state and adverse outcomes, in general population. Limited data are available on the relationship between polypharmacy and adverse outcomes in atrial fibrillation (AF). We describe the prevalence of polypharmacy and AF, and its association with major adverse events, such as stroke and cardiovascular (CV) death. METHODS AND RESULTS: For this study, we analysed all AFFIRM Trial patients with complete pharmacological data. Polypharmacy was recorded in 40 % of 4056 AFpatients. The crude incidence of CV death was 3.45 % patient-years among patients with polypharmacy, vs 1.65 % patient-years without polypharmacy. Kaplan-Meier analysis showed that patients with polypharmacy had a higher cumulative incidence of CV death (p < 0.001). Cox regression analysis demonstrated that female gender (p = 0.038), diabetes mellitus (p = 0.029), previous myocardial infarction (MI) (p = 0.004), prior stroke (p = 0.011) and polypharmacy (p = 0.029) were independently associated with CV death. Polypharmacy was associated with an adjusted relative risk of 1.30 (95 % CI 1.03-1.64) for CV death. A linear increase in the number of drugs was significantly associated with CV death. No significant association was found with stroke occurrence. CONCLUSIONS: Polypharmacy is highly prevalent in AFpatients and associated with a worse clinical outcome, conferring 30 % excess relative risk for CV death. Thus, polypharmacy may be a health status marker. Strategies to reduce inappropriate prescription and polypharmacy should be tested in prospective longitudinal studies of AFpatients.
Authors: Ian A Scott; Sarah N Hilmer; Emily Reeve; Kathleen Potter; David Le Couteur; Deborah Rigby; Danijela Gnjidic; Christopher B Del Mar; Elizabeth E Roughead; Amy Page; Jesse Jansen; Jennifer H Martin Journal: JAMA Intern Med Date: 2015-05 Impact factor: 21.873
Authors: Jean S Kutner; Patrick J Blatchford; Donald H Taylor; Christine S Ritchie; Janet H Bull; Diane L Fairclough; Laura C Hanson; Thomas W LeBlanc; Greg P Samsa; Steven Wolf; Noreen M Aziz; David C Currow; Betty Ferrell; Nina Wagner-Johnston; S Yousuf Zafar; James F Cleary; Sandesh Dev; Patricia S Goode; Arif H Kamal; Cordt Kassner; Elizabeth A Kvale; Janelle G McCallum; Adeboye B Ogunseitan; Steven Z Pantilat; Russell K Portenoy; Maryjo Prince-Paul; Jeff A Sloan; Keith M Swetz; Charles F Von Gunten; Amy P Abernethy Journal: JAMA Intern Med Date: 2015-05 Impact factor: 21.873
Authors: Justine E F Moonen; Jessica C Foster-Dingley; Wouter de Ruijter; Jeroen van der Grond; Anne Suzanne Bertens; Mark A van Buchem; Jacobijn Gussekloo; Huub A Middelkoop; Marieke J H Wermer; Rudi G J Westendorp; Anton J M de Craen; Roos C van der Mast Journal: JAMA Intern Med Date: 2015-10 Impact factor: 21.873
Authors: Siobhan Dumbreck; Angela Flynn; Moray Nairn; Martin Wilson; Shaun Treweek; Stewart W Mercer; Phil Alderson; Alex Thompson; Katherine Payne; Bruce Guthrie Journal: BMJ Date: 2015-03-11
Authors: Philip L Mar; Rakesh Gopinathannair; Brooke E Gengler; Mina K Chung; Arturo Perez; Jonathan Dukes; Michael D Ezekowitz; Dhanunjaya Lakkireddy; Gregory Y H Lip; Mike Miletello; Peter A Noseworthy; James Reiffel; James E Tisdale; Brian Olshansky Journal: Circ Arrhythm Electrophysiol Date: 2022-05-27
Authors: Hisham A Badreldin; Jahad Alghamdi; Omar Alshaya; Abdulmajeed Alshehri; Lamya Alreshoud; Renad Altoukhi; Senthilvel Vasudevan; Wesam W Ismail; Mohamed Salih Aziz Mohamed Journal: Int J Gen Med Date: 2020-07-22
Authors: Agnieszka Kotalczyk; Michał Mazurek; Zbigniew Kalarus; Tatjana S Potpara; Gregory Y H Lip Journal: Nat Rev Cardiol Date: 2020-10-27 Impact factor: 32.419
Authors: Jeroen Jaspers Focks; Marc A Brouwer; Daniel M Wojdyla; Laine Thomas; Renato D Lopes; Jeffrey B Washam; Fernando Lanas; Denis Xavier; Steen Husted; Lars Wallentin; John H Alexander; Christopher B Granger; Freek W A Verheugt Journal: BMJ Date: 2016-06-15
Authors: Manon C Stam-Slob; Frank L J Visseren; J Wouter Jukema; Yolanda van der Graaf; Neil R Poulter; Ajay Gupta; Naveed Sattar; Peter W Macfarlane; Patricia M Kearney; Anton J M de Craen; Stella Trompet Journal: Clin Res Cardiol Date: 2016-08-23 Impact factor: 5.460
Authors: Nemin Chen; Aniqa B Alam; Pamela L Lutsey; Richard F MacLehose; J'Neka S Claxton; Lin Y Chen; Alanna M Chamberlain; Alvaro Alonso Journal: J Am Heart Assoc Date: 2020-05-23 Impact factor: 5.501